{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T09:55:54Z","timestamp":1760954154053,"version":"3.40.5"},"reference-count":107,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,12,14]],"date-time":"2019-12-14T00:00:00Z","timestamp":1576281600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,12,14]],"date-time":"2019-12-14T00:00:00Z","timestamp":1576281600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s11033-019-05227-2","type":"journal-article","created":{"date-parts":[[2019,12,16]],"date-time":"2019-12-16T15:56:39Z","timestamp":1576511799000},"page":"1435-1443","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Aldehyde dehydrogenase-positive melanoma stem cells in tumorigenesis, drug resistance and anti-neoplastic immunotherapy"],"prefix":"10.1007","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4408-7289","authenticated-orcid":false,"given":"Simin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1442-275X","authenticated-orcid":false,"given":"Fazhi","family":"Qi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,12,14]]},"reference":[{"key":"5227_CR1","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","volume":"161","author":"The Cancer Genome Atlas Network","year":"2015","unstructured":"The Cancer Genome Atlas Network (2015) Genomic classification of cutaneous melanoma. Cell 161:1681\u20131696","journal-title":"Cell"},{"key":"5227_CR2","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1101\/gad.191999.112","volume":"26","author":"H Tsao","year":"2012","unstructured":"Tsao H, Chin L, Garraway LA et al (2012) Melanoma: from mutations to medicine. Genes Dev 26:1131\u20131155","journal-title":"Genes Dev"},{"key":"5227_CR3","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/labinvest.2016.142","volume":"97","author":"M Kiuru","year":"2017","unstructured":"Kiuru M, Busam KJ (2017) The NF1 gene in tumor syndromes and melanoma. Lab Investig 97:146\u2013157","journal-title":"Lab Investig"},{"key":"5227_CR4","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2217\/mmt.15.2","volume":"2","author":"V Villani","year":"2015","unstructured":"Villani V, Sabbatino F, Ferrone CR et al (2015) Melanoma initiating cells: where do we stand? Melanoma Manag 2:109\u2013114","journal-title":"Melanoma Manag"},{"key":"5227_CR5","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/1479-7364-2-2-138","volume":"2","author":"V Vasiliou","year":"2005","unstructured":"Vasiliou V, Nebert DW (2005) Analysis and update of the human aldehyde dehydrogenase (ALDH) gene family. Hum Genomics 2:138\u2013143","journal-title":"Hum Genomics"},{"key":"5227_CR6","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/3904645","author":"G Vassalli","year":"2019","unstructured":"Vassalli G (2019) Aldehyde dehydrogenases: not just markers, but functional regulators of stem cells. Stem Cells Int.https:\/\/doi.org\/10.1155\/2019\/3904645","journal-title":"Stem Cells Int"},{"key":"5227_CR7","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1186\/1479-7364-5-4-283","volume":"5","author":"B Jackson","year":"2011","unstructured":"Jackson B, Brocker C, Thompson DC et al (2011) Update on the aldehyde dehydrogenase gene (ALDH) superfamily. Hum Genomics 5:283\u2013303","journal-title":"Hum Genomics"},{"key":"5227_CR8","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/jbt.10057","volume":"17","author":"NE Sl\u00e1dek","year":"2003","unstructured":"Sl\u00e1dek NE (2003) Human aldehyde dehydrogenases: potential pathological, pharmacological, and toxicological impact. J Biochem Mol Toxicol 17:7\u201323","journal-title":"J Biochem Mol Toxicol"},{"key":"5227_CR9","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.3390\/ijms18061116","volume":"18","author":"HK Na","year":"2017","unstructured":"Na HK, Lee JY (2017) Molecular basis of alcohol-related gastric and colon cancer. Int J Mol Sci 18:1116","journal-title":"Int J Mol Sci"},{"key":"5227_CR10","first-page":"127","volume":"9","author":"G Castelli","year":"2017","unstructured":"Castelli G, Pelosi E, Testa U (2017) Liver cancer: molecular characterization, clonal evolution and cancer. Stem Cells Cancers 9:127","journal-title":"Stem Cells Cancers"},{"key":"5227_CR11","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.3390\/ijms18091849","volume":"18","author":"LYW Bourguignon","year":"2017","unstructured":"Bourguignon LYW, Christine E, Marisa S (2017) Activation of matrix hyaluronan-mediated CD44 signaling, epigenetic regulation and chemoresistance in head and neck cancer stem cells. Int J Mol Sci 18:1849","journal-title":"Int J Mol Sci"},{"key":"5227_CR12","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/978-3-319-24932-2_4","volume":"890","author":"R Suresh","year":"2015","unstructured":"Suresh R, Ali S, Ahmad A et al (2015) The role of cancer stem cells in recurrent and drug-resistant lung cancer. Adv Exp Med Biol 890:57\u201374","journal-title":"Adv Exp Med Biol"},{"issue":"15","key":"5227_CR13","doi-asserted-by":"crossref","first-page":"12503","DOI":"10.18632\/oncotarget.23605","volume":"9","author":"S Yan","year":"2017","unstructured":"Yan S, Wu G (2017) Could ALDH2*2 be the reason for low incidence and mortality of ovarian cancer for East Asia women? Oncotarget 9(15):12503\u201312512","journal-title":"Oncotarget"},{"key":"5227_CR14","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.4161\/cc.26417","volume":"12","author":"B Corominas-Faja","year":"2013","unstructured":"Corominas-Faja B, Oliveras-Ferraros C, Cuy\u00e0s E (2013) Stem cell-like ALDH(bright) cellular states in EGFR-mutant non-small cell lung cancer: a novel mechanism of acquired resistance to erlotinib targetable with the natural polyphenol silibinin. Cell Cycle 12:3390\u20133404","journal-title":"Cell Cycle"},{"key":"5227_CR15","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1007\/s12282-017-0761-4","volume":"24","author":"T Uomori","year":"2017","unstructured":"Uomori T, Horimoto Y, Mogushi K et al (2017) Relationship between alcohol metabolism and chemotherapy-induced emetic events in breast cancer patients. Breast Cancer 24:702\u2013707","journal-title":"Breast Cancer"},{"key":"5227_CR16","doi-asserted-by":"crossref","first-page":"108822","DOI":"10.1016\/j.cbi.2019.108822","volume":"314","author":"JM Samson","year":"2019","unstructured":"Samson JM, Ravindran Menon D, Smith DE et al (2019) Clinical implications of ALDH1A1 and ALDH1A3 mRNA expression in melanoma subtypes. Chem Biol Interact 314:108822","journal-title":"Chem Biol Interact"},{"key":"5227_CR17","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/jcb.23406","volume":"113","author":"PM Amann","year":"2012","unstructured":"Amann PM, Hofmann C, Freudenberger M et al (2012) Expression and activity of alcohol and aldehyde dehydrogenases in melanoma cells and in melanocytes. J Cell Biochem 113:792\u2013299","journal-title":"J Cell Biochem"},{"key":"5227_CR18","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1002\/jcp.25796","volume":"232","author":"CE Brinckerhoff","year":"2017","unstructured":"Brinckerhoff CE (2017) Cancer stem cells (CSCs) in melanoma. J Cell Physiol 232:2674\u20132678","journal-title":"J Cell Physiol"},{"key":"5227_CR19","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/nature07567","volume":"456","author":"E Quintana","year":"2008","unstructured":"Quintana E, Shackleton M, Sabel MS et al (2008) Efficient tumour formation by single human melanoma cells. Nature 456:593\u2013598","journal-title":"Nature"},{"key":"5227_CR20","doi-asserted-by":"crossref","first-page":"6477","DOI":"10.4049\/jimmunol.174.10.6477","volume":"174","author":"LD Shultz","year":"2005","unstructured":"Shultz LD, Lyons BL, Burzenski LM et al (2005) Human lymphoid and myeloid cell development in NOD\/LtSz-scid IL2R\u03b3null mice engrafted with mobilized human hemopoietic stem cells. J Immunol 174:6477\u20136489","journal-title":"J Immunol"},{"key":"5227_CR21","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.semcancer.2019.06.019","volume":"59","author":"M Marzagalli","year":"2019","unstructured":"Marzagalli M, Raimondi M, Fontana F et al (2019) Cellular and molecular biology of cancer stem cells in melanoma: possible therapeutic implications. Semin Cancer Biol 59:221\u2013235","journal-title":"Semin Cancer Biol"},{"key":"5227_CR22","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1073\/pnas.1009069108","volume":"108","author":"P Schmidt","year":"2011","unstructured":"Schmidt P, Kopecky C, Hombach A et al (2011) Eradication of melanomas by targeted elimination of a minor subset of tumor cells. Proc Natl Acad Sci USA 108:2474\u20132479","journal-title":"Proc Natl Acad Sci USA"},{"key":"5227_CR23","doi-asserted-by":"crossref","first-page":"22","DOI":"10.18632\/oncotarget.437","volume":"3","author":"M Schlaak","year":"2012","unstructured":"Schlaak M, Schmidt P, Bangard C et al (2012) Regression of metastatic melanoma in a patient by antibody targeting of cancer stem cells. Oncotarget 3:22\u201330","journal-title":"Oncotarget"},{"key":"5227_CR24","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/1440-1681.13049","volume":"46","author":"JM Gon\u00e7alves","year":"2019","unstructured":"Gon\u00e7alves JM, Silva CAB, Rivero ERC et al (2019) Inhibition of cancer stem cells promoted by pimozide. Cli Exp Pharmacol Physiol 46:116\u2013125","journal-title":"Cli Exp Pharmacol Physiol"},{"key":"5227_CR25","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1007\/s12015-010-9208-4","volume":"7","author":"I Ma","year":"2011","unstructured":"Ma I, Allan AL (2011) The role of human aldehyde dehydrogenase in normal and cancer stem cells. Stem Cell Rev 7:292\u2013306","journal-title":"Stem Cell Rev"},{"key":"5227_CR26","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.stem.2007.08.014","volume":"1","author":"C Ginestier","year":"2007","unstructured":"Ginestier C, Hur M, Charafe-Jauffret E (2007) ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1:555\u2013567","journal-title":"Cell Stem Cell"},{"key":"5227_CR27","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1158\/1541-7786.MCR-08-0393","volume":"7","author":"F Jiang","year":"2009","unstructured":"Jiang F (2009) Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer. Mol Cancer Res 7:330\u2013338","journal-title":"Mol Cancer Res"},{"key":"5227_CR28","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.canlet.2015.08.018","volume":"369","author":"X Xu","year":"2015","unstructured":"Xu X, Chai S, Wang P et al (2015) Aldehyde dehydrogenases and cancer stem cells. Cancer Lett 369:50\u201357","journal-title":"Cancer Lett"},{"key":"5227_CR29","doi-asserted-by":"crossref","first-page":"e10731","DOI":"10.1371\/journal.pone.0010731","volume":"5","author":"L Prasmickaite","year":"2010","unstructured":"Prasmickaite L, Engesaeter B, Skrbo N, Hellenes T et al (2010) Aldehyde dehydrogenase (ALDH) activity does not select for cells with enhanced aggressive properties in malignant melanoma. PLoS ONE 5:e10731","journal-title":"PLoS ONE"},{"key":"5227_CR30","doi-asserted-by":"crossref","first-page":"7538","DOI":"10.1158\/0008-5472.CAN-08-4626","volume":"69","author":"J Yang","year":"2009","unstructured":"Yang J, Price MA, Li GY et al (2009) Melanoma proteoglycan modifies gene expression to stimulate tumor cell motility, growth, and epithelial-to-mesenchymal transition. Cancer Res 69:7538\u20137547","journal-title":"Cancer Res"},{"key":"5227_CR31","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1038\/jid.2010.237","volume":"130","author":"JB Boonyaratanakornkit","year":"2010","unstructured":"Boonyaratanakornkit JB, Yue L, Strachan LR et al (2010) Selection of tumorigenic melanoma cells using ALDH. J Investig Dermatol 130:2799\u20132808","journal-title":"J Investig Dermatol"},{"key":"5227_CR32","doi-asserted-by":"crossref","first-page":"e113910","DOI":"10.1371\/journal.pone.0113910","volume":"9","author":"H Ohmura-Kakutani","year":"2014","unstructured":"Ohmura-Kakutani H, Akiyama K, Maishi N et al (2014) Identification of tumor endothelial cells with high aldehyde dehydrogenase activity and a highly angiogenic phenotype. PLoS ONE 9:e113910","journal-title":"PLoS ONE"},{"key":"5227_CR33","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/vco.12019","volume":"13","author":"HM Wilson-Robles","year":"2015","unstructured":"Wilson-Robles HM, Daly M, Pfent C et al (2015) Identification and evaluation of putative tumour-initiating cells in canine malignant melanoma cell lines. Vet Comp Oncol 13:60\u201369","journal-title":"Vet Comp Oncol"},{"key":"5227_CR34","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1002\/stem.1193","volume":"30","author":"Y Luo","year":"2012","unstructured":"Luo Y, Dallaglio K, Chen Y et al (2012) ALDH1A isozymes are markers of human melanoma stem cells and potential therapeutic targets. Stem Cells 30:2100\u20132113","journal-title":"Stem Cells"},{"key":"5227_CR35","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/978-3-319-22539-5_8","volume":"167","author":"MA Wilson","year":"2016","unstructured":"Wilson MA, Schuchter LM (2016) Chemotherapy for melanoma. Cancer Treat Res 167:209\u2013229","journal-title":"Cancer Treat Res"},{"key":"5227_CR36","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nrc3218","volume":"12","author":"KT Flaherty","year":"2012","unstructured":"Flaherty KT, Hodi FS, Fisher DE (2012) From genes to drugs: targeted strategies for melanoma. Nat Rev Cancer 12:349\u2013361","journal-title":"Nat Rev Cancer"},{"key":"5227_CR37","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","volume":"364","author":"PB Chapman","year":"2011","unstructured":"Chapman PB, Hauschild A, Robert C et al (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507\u20132516","journal-title":"N Engl J Med"},{"key":"5227_CR38","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1097\/CAD.0000000000000741","volume":"30","author":"S Li","year":"2018","unstructured":"Li S, Wu X, Chen P et al (2018) Interferon-\u03b1 versus interleukin-2 in Chinese patients with malignant melanoma: a randomized, controlled, trial. Anticancer Drugs 30:402\u2013409","journal-title":"Anticancer Drugs"},{"key":"5227_CR39","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s40880-017-0179-6","volume":"36","author":"A Simon","year":"2017","unstructured":"Simon A, Kourie HR, Kerger J (2017) Is there still a role for cytotoxic chemotherapy after targeted therapy and immunotherapy in metastatic melanoma? a case report and literature review. Chin J Cancer 36:10","journal-title":"Chin J Cancer"},{"key":"5227_CR40","first-page":"2259","volume":"44","author":"GH Heppner","year":"1984","unstructured":"Heppner GH (1984) Tumor heterogeneity. Cancer Res 44:2259\u20132265","journal-title":"Cancer Res"},{"key":"5227_CR41","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1158\/1535-7163.MCT-16-0535","volume":"16","author":"A Ahn","year":"2017","unstructured":"Ahn A, Chatterjee A, Eccles MR (2017) The slow cycling phenotype: a growing problem for treatment resistance in melanoma. Mol Cancer Ther 16:1002\u20131009","journal-title":"Mol Cancer Ther"},{"key":"5227_CR42","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s12916-017-0900-y","volume":"15","author":"DR Caswell","year":"2017","unstructured":"Caswell DR, Swanton C (2017) The role of tumour heterogeneity and clonal cooperativity in metastasis, immune evasion and clinical outcome. BMC Med 15:133","journal-title":"BMC Med"},{"key":"5227_CR43","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1158\/2159-8290.CD-13-0642","volume":"4","author":"H Shi","year":"2014","unstructured":"Shi H, Hugo W, Kong X et al (2014) Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov 4:80\u201393","journal-title":"Cancer Discov"},{"key":"5227_CR44","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1038\/onc.2014.372","volume":"34","author":"DR Menon","year":"2014","unstructured":"Menon DR, Das S, Krepler C et al (2014) A stress-induced early innate response causes multidrug tolerance in melanoma. Oncogene 34:4448\u20134459","journal-title":"Oncogene"},{"key":"5227_CR45","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.2174\/138920111798808437","volume":"12","author":"A Busse","year":"2011","unstructured":"Busse A, Keilholz U (2011) Role of TGF-\u03b2 in melanoma. Curr Pharm Biotechnol 12:2165\u20132175","journal-title":"Curr Pharm Biotechnol"},{"key":"5227_CR46","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1016\/j.cub.2015.09.054","volume":"25","author":"G Cantelli","year":"2015","unstructured":"Cantelli G, Orgaz JL, Rodr\u00edguez-Hern\u00e1ndez I et al (2015) TGF-\u03b2-induced transcription sustains amoeboid melanoma migration and dissemination. Curr Biol 25:2899\u20132914","journal-title":"Curr Biol"},{"key":"5227_CR47","doi-asserted-by":"crossref","first-page":"81995","DOI":"10.18632\/oncotarget.13226","volume":"7","author":"LC Spender","year":"2016","unstructured":"Spender LC, Ferguson GJ, Liu S et al (2016) Mutational activation of BRAF confers sensitivity to transforming growth factor beta inhibitors in human cancer cells. Oncotarget 7:81995\u201382012","journal-title":"Oncotarget"},{"key":"5227_CR48","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1038\/s41467-019-09634-8","volume":"10","author":"S Li","year":"2019","unstructured":"Li S, Song Y, Quach C et al (2019) Transcriptional regulation of autophagy-lysosomal function in BRAF-driven melanoma progression and chemoresistance. Nat Commun 10:1693","journal-title":"Nat Commun"},{"key":"5227_CR49","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.bbrc.2010.01.028","volume":"392","author":"Y Teng","year":"2010","unstructured":"Teng Y, Wang X, Wang Y et al (2010) Wnt\/\u03b2-catenin signaling regulates cancer stem cells in lung cancer A549 cells. Biochem Biophys Res Commun 392:373\u2013379","journal-title":"Biochem Biophys Res Commun"},{"key":"5227_CR50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ctrv.2016.06.009","volume":"49","author":"G Xue","year":"2016","unstructured":"Xue G, Romano E, Massi D et al (2016) Wnt\/\u03b2-catenin signaling in melanoma: preclinical rationale and novel therapeutic insights. Cancer Treat Rev 49:1\u201312","journal-title":"Cancer Treat Rev"},{"key":"5227_CR51","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nature24040","volume":"550","author":"H Lu","year":"2017","unstructured":"Lu H, Liu S, Zhang G et al (2017) PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas. Nature 550:133\u2013136","journal-title":"Nature"},{"key":"5227_CR52","doi-asserted-by":"crossref","first-page":"82256","DOI":"10.18632\/oncotarget.19286","volume":"8","author":"N Suleymanova","year":"2017","unstructured":"Suleymanova N, Crudden C, Worrall C et al (2017) Enhanced response of melanoma cells to MEK inhibitors following unbiased IGF-1R down-regulation. Oncotarget 8:82256\u201382267","journal-title":"Oncotarget"},{"key":"5227_CR53","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1038\/onc.2010.598","volume":"30","author":"Y Cheli","year":"2011","unstructured":"Cheli Y, Guiliano S, Botton T et al (2011) Mitf is the key molecular switch between mouse or human melanoma initiating cells and their differentiated progeny. Oncogene 30:2307\u20132318","journal-title":"Oncogene"},{"key":"5227_CR54","doi-asserted-by":"crossref","first-page":"5712","DOI":"10.1038\/ncomms6712","volume":"5","author":"J M\u00fcller","year":"2013","unstructured":"M\u00fcller J, Krijgsman O, Tsoi J (2013) Low MITF\/AXL ratio predicts early resistance to multiple targeted drugs in melanoma. Nat Commun 5:5712","journal-title":"Nat Commun"},{"key":"5227_CR55","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/nature13121","volume":"508","author":"C Sun","year":"2014","unstructured":"Sun C, Wang L, Huang S et al (2014) Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. Nature 508:118\u2013122","journal-title":"Nature"},{"key":"5227_CR56","doi-asserted-by":"crossref","first-page":"5453","DOI":"10.1172\/JCI76611","volume":"124","author":"D Zhao","year":"2014","unstructured":"Zhao D, Mo Y, Li MT et al (2014) NOTCH-induced aldehyde dehydrogenase 1A1 deacetylation promotes breast cancer stem cells. J Clin Investig 124:5453\u20135465","journal-title":"J Clin Investig"},{"key":"5227_CR57","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.4161\/cc.6.15.4545","volume":"6","author":"YJ Chen","year":"2007","unstructured":"Chen YJ, Sims-Mourtada J, Izzo J et al (2007) Targeting the hedgehog pathway to mitigate treatment resistance. Cell Cycle 6:1826\u20131830","journal-title":"Cell Cycle"},{"key":"5227_CR58","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.biopha.2013.04.005","volume":"67","author":"R Januchowski","year":"2013","unstructured":"Januchowski R, Wojtowicz K, Zabel M (2013) The role of aldehyde dehydrogenase (ALDH) in cancer drug resistance. Biomed Pharmacother 67:669\u2013680","journal-title":"Biomed Pharmacother"},{"key":"5227_CR59","doi-asserted-by":"crossref","first-page":"4234","DOI":"10.1158\/1078-0432.CCR-08-1479","volume":"15","author":"T Tomonori","year":"2009","unstructured":"Tomonori T, Koji M, Kenzo S et al (2009) Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers. Clin Cancer Res 15:4234\u20134241","journal-title":"Clin Cancer Res"},{"key":"5227_CR60","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s10549-011-1692-y","volume":"133","author":"AK Croker","year":"2012","unstructured":"Croker AK, Allan AL (2012) Inhibition of aldehyde dehydrogenase (ALDH) activity reduces chemotherapy and radiation resistance of stem-like ALDH hi CD44+ human breast cancer cells. Breast Cancer Res Treat 133:75\u201387","journal-title":"Breast Cancer Res Treat"},{"key":"5227_CR61","first-page":"390","volume":"293","author":"JS Moreb","year":"2000","unstructured":"Moreb JS, Maccow C, Schweder M et al (2000) Expression of antisense RNA to aldehyde dehydrogenase class-1 sensitizes tumor cells to 4-hydroperoxycyclophosphamide in vitro. J Pharmacol Exp Ther 293:390\u2013396","journal-title":"J Pharmacol Exp Ther"},{"key":"5227_CR62","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s00432-010-0913-9","volume":"137","author":"QL Sun","year":"2011","unstructured":"Sun QL, Sha HF, Yang XH et al (2011) Comparative proteomic analysis of paclitaxel sensitive A549 lung adenocarcinoma cell line and its resistant counterpart A549-Taxol. J Cancer Res Clin Oncol 137:521\u2013532","journal-title":"J Cancer Res Clin Oncol"},{"key":"5227_CR63","doi-asserted-by":"crossref","first-page":"3186","DOI":"10.1158\/1535-7163.MCT-10-0563","volume":"9","author":"CN Landen","year":"2010","unstructured":"Landen CN, Goodman B, Katre AA et al (2010) Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer. Mol Cancer Ther 9:3186\u20133199","journal-title":"Mol Cancer Ther"},{"key":"5227_CR64","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.biocel.2016.07.017","volume":"78","author":"R Januchowski","year":"2016","unstructured":"Januchowski R, Wojtowicz K, Sterzy\u0144ska K et al (2016) Inhibition of ALDH1A1 activity decreases expression of drug transporters and reduces chemotherapy resistance in ovarian cancer cell lines. Int J Biochem Cell Biol 78:248\u2013259","journal-title":"Int J Biochem Cell Biol"},{"key":"5227_CR65","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.gene.2013.03.056","volume":"525","author":"A Koz\u0142owska","year":"2013","unstructured":"Koz\u0142owska A, Mackiewicz J, Mackiewicz A (2013) Therapeutic gene modified cell based cancer vaccines. Gene 525:200\u2013207","journal-title":"Gene"},{"key":"5227_CR66","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.mam.2013.10.003","volume":"39","author":"GF Murphy","year":"2014","unstructured":"Murphy GF, Wilson BJ, Girouard SD et al (2014) Stem cells and targeted approaches to melanoma cure. Mol Aspects Med 39:33\u201349","journal-title":"Mol Aspects Med"},{"key":"5227_CR67","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1471-2210-10-12","volume":"10","author":"L Tang","year":"2010","unstructured":"Tang L, Bergevoet SM, Gilissen C et al (2010) Hematopoietic stem cells exhibit a specific ABC transporter gene expression profile clearly distinct from other stem cells. BMC Pharmacol 10:12","journal-title":"BMC Pharmacol"},{"key":"5227_CR68","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.apsb.2013.02.006","volume":"3","author":"L Han","year":"2013","unstructured":"Han L, Shi S, Gong T et al (2013) Cancer stem cells: therapeutic implications and perspectives in cancer therapy. Acta Pharm Sin B 3:65\u201375","journal-title":"Acta Pharm Sin B"},{"key":"5227_CR69","doi-asserted-by":"crossref","first-page":"988","DOI":"10.2174\/1568009618666180425142653","volume":"18","author":"L Zheng","year":"2018","unstructured":"Zheng L, Pan J (2018) The anti-malarial drug artesunate blocks wnt\/\u03b2-catenin pathway and inhibits growth, migration and invasion of uveal melanoma cells. Curr Cancer Drug Targ 18:988\u2013998","journal-title":"Curr Cancer Drug Targ"},{"key":"5227_CR70","doi-asserted-by":"crossref","first-page":"3908","DOI":"10.1038\/onc.2013.373","volume":"33","author":"IG Kim","year":"2014","unstructured":"Kim IG, Kim SY, Choi SI et al (2014) Fibulin-3-mediated inhibition of epithelial-to-mesenchymal transition and self-renewal of ALDH+ lung cancer stem cells through IGF1R signaling. Oncogene 33:3908\u20133917","journal-title":"Oncogene"},{"key":"5227_CR71","doi-asserted-by":"crossref","first-page":"6882","DOI":"10.1002\/jcb.26885","volume":"119","author":"N Jin","year":"2018","unstructured":"Jin N, Zhu X, Cheng F et al (2018) Disulfiram\/copper targets stem cell-like ALDH+ population of multiple myeloma by inhibition of ALDH1A1 and Hedgehog pathway. J Cell Biochem 119:6882\u20136893","journal-title":"J Cell Biochem"},{"key":"5227_CR72","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/CMR.0000000000000144","volume":"25","author":"L Yue","year":"2015","unstructured":"Yue L, Huang ZM, Fong S et al (2015) Targeting ALDH1 to decrease tumorigenicity, growth and metastasis of human melanoma. Melanoma Res 25:138\u2013148","journal-title":"Melanoma Res"},{"key":"5227_CR73","first-page":"2816","volume":"6","author":"YW Ma","year":"2016","unstructured":"Ma YW, Liu YZ, Pan JX (2016) Verteporfin induces apoptosis and eliminates cancer stem-like cells in uveal melanoma in the absence of light activation. Am J Cancer Res 6:2816\u20132830","journal-title":"Am J Cancer Res"},{"key":"5227_CR74","doi-asserted-by":"crossref","first-page":"20253","DOI":"10.1038\/srep20253","volume":"6","author":"Y Zhu","year":"2016","unstructured":"Zhu Y, Ye T, Yu X et al (2016) Nifuroxazide exerts potent anti-tumor and anti-metastasis activity in melanoma. Sci Rep 6:20253","journal-title":"Sci Rep"},{"key":"5227_CR75","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1016\/j.chembiol.2018.09.005","volume":"25","author":"S Sarvi","year":"2018","unstructured":"Sarvi S, Crispin R, Lu Y et al (2018) ALDH1 bio-activates nifuroxazide to eradicate ALDHHigh melanoma-initiating cells. Cell Chem Biol 25:1456-1469.e6","journal-title":"Cell Chem Biol"},{"key":"5227_CR76","doi-asserted-by":"crossref","first-page":"6914","DOI":"10.18632\/oncotarget.14321","volume":"8","author":"T Petrachi","year":"2017","unstructured":"Petrachi T, Romagnani A, Albini A et al (2017) Therapeutic potential of the metabolic modulator phenformin in targeting the stem cell compartment in melanoma. Oncotarget 8:6914\u20136928","journal-title":"Oncotarget"},{"key":"5227_CR77","doi-asserted-by":"crossref","first-page":"887","DOI":"10.3892\/ijo.2017.4079","volume":"51","author":"B Zhang","year":"2017","unstructured":"Zhang B, Zhang J, Pan J (2017) Pristimerin effectively inhibits the malignant phenotypes of uveal melanoma cells by targeting NF-\u03baB pathway. Int J Oncol 51:887\u2013898","journal-title":"Int J Oncol"},{"key":"5227_CR78","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ejmech.2018.06.046","volume":"156","author":"S Liu","year":"2018","unstructured":"Liu S, Gao X, Zhang L et al (2018) A novel anti-cancer stem cells compound optimized from the natural symplostatin 4 scaffold inhibits Wnt\/\u03b2-catenin signaling pathway. Eur J Med Chem 156:21\u201342","journal-title":"Eur J Med Chem"},{"key":"5227_CR79","first-page":"e50561","volume":"83","author":"Q Li","year":"2014","unstructured":"Li Q, Lu L, Tao H et al (2014) Generation of a novel dendritic-cell vaccine using melanoma and squamous cancer stem cells. J Vis Exp 83:e50561","journal-title":"J Vis Exp"},{"key":"5227_CR80","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1158\/0008-5472.CAN-11-1400","volume":"72","author":"N Ning","year":"2012","unstructured":"Ning N, Pan Q, Zheng F et al (2012) Cancer stem cell vaccination confers significant antitumor immunity. Cancer Res 72:1853\u20131864","journal-title":"Cancer Res"},{"key":"5227_CR81","doi-asserted-by":"crossref","first-page":"310","DOI":"10.3390\/cancers11030310","volume":"11","author":"N Badrinath","year":"2019","unstructured":"Badrinath N, Yoo SY (2019) Recent advances in cancer stem cell-targeted immunotherapy. Cancers 11:310","journal-title":"Cancers"},{"key":"5227_CR82","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.canlet.2016.01.021","volume":"374","author":"A Dashti","year":"2016","unstructured":"Dashti A, Ebrahimi M, Hadjati J et al (2016) Dendritic cell based immunotherapy using tumor stem cells mediates potent antitumor immune responses. Cancer Lett 374:175\u2013185","journal-title":"Cancer Lett"},{"key":"5227_CR83","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1002\/stem.102","volume":"27","author":"Q Xu","year":"2009","unstructured":"Xu Q, Liu G, Yuan X et al (2009) Antigen-specific T-cell response from dendritic cell vaccination using cancer stem-like cell-associated antigens. Stem Cells 27:1734\u20131740","journal-title":"Stem Cells"},{"key":"5227_CR84","doi-asserted-by":"crossref","first-page":"e990767","DOI":"10.4161\/2162402X.2014.990767","volume":"4","author":"H Lu Lin. Tao","year":"2015","unstructured":"Lu Lin. Tao H, Chang AE et al (2015) Cancer stem cell vaccine inhibits metastases of primary tumors and induces humoral immune responses against cancer stem cells. Oncoimmunology 4:e990767","journal-title":"Oncoimmunology"},{"key":"5227_CR85","doi-asserted-by":"crossref","first-page":"4661","DOI":"10.1158\/0008-5472.CAN-15-2664","volume":"76","author":"Y Hu","year":"2016","unstructured":"Hu Y, Lu L, Xia Y et al (2016) Therapeutic efficacy of cancer stem cell vaccines in the adjuvant setting. Cancer Res 76:4661\u20134672","journal-title":"Cancer Res"},{"key":"5227_CR86","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1158\/0008-5472.CAN-12-4100","volume":"73","author":"J Duraiswamy","year":"2013","unstructured":"Duraiswamy J. Kaluza KM. Freeman GJ et al ( (2013) Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res 73:3591\u20133603","journal-title":"Cancer Res"},{"key":"5227_CR87","doi-asserted-by":"crossref","first-page":"3571","DOI":"10.1158\/1078-0432.CCR-15-2665","volume":"22","author":"Y Lee","year":"2016","unstructured":"Lee Y, Shin JH, Longmire M et al (2016) Cd44+ cells in head and neck squamous cell carcinoma suppress T-cell-mediated immunity by selective constitutive and inducible expression of PD-L1. Clin Cancer Res 22:3571\u20133581","journal-title":"Clin Cancer Res"},{"key":"5227_CR88","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1111\/cas.12406","volume":"105","author":"K Tamai","year":"2014","unstructured":"Tamai K, Nakamura M, Mizuma M et al (2014) Suppressive expression of CD274 increases tumorigenesis and cancer stem cell phenotypes in cholangiocarcinoma. Cancer Sci 105:667\u2013674","journal-title":"Cancer Sci"},{"key":"5227_CR89","first-page":"1293201","volume":"2017","author":"F Zheng","year":"2017","unstructured":"Zheng F, Dang J, Zha H et al (2017) PD-L1 promotes self-renewal and tumorigenicity of malignant melanoma initiating cells. Biomed Res Int 2017:1293201","journal-title":"Biomed Res Int"},{"key":"5227_CR90","doi-asserted-by":"crossref","first-page":"e7325","DOI":"10.1097\/MD.0000000000007325","volume":"96","author":"C Hao","year":"2017","unstructured":"Hao C, Tian J, Liu H et al (2017) Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma: A systematic review and meta-analysis of randomized controlled trials. Medicine 96:e7325","journal-title":"Medicine"},{"key":"5227_CR91","first-page":"6163","volume":"16","author":"B Zhang","year":"2018","unstructured":"Zhang B, Dang J, Ba D et al (2018) Potential function of CTLA-4 in the tumourigenic capacity of melanoma stem cells. Oncol Lett 16:6163\u20136170","journal-title":"Oncol Lett"},{"key":"5227_CR92","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/CJI.0000000000000242","volume":"41","author":"F Zheng","year":"2018","unstructured":"Zheng F, Dang J, Zhang H et al (2018) Cancer stem cell vaccination with PD-L1 and CTLA-4 blockades enhances the eradication of melanoma stem cells in a mouse tumor model. J Immunother 41:361\u2013368","journal-title":"J Immunother"},{"key":"5227_CR93","doi-asserted-by":"crossref","first-page":"4347","DOI":"10.1158\/1078-0432.CCR-13-0061","volume":"19","author":"L Gammaitoni","year":"2013","unstructured":"Gammaitoni L, Giraudo L, Leuci V et al (2013) Effective activity of cytokine-induced killer cells against autologous metastatic melanoma including cells with stemness features. Clin Cancer Res 19:4347\u20134358","journal-title":"Clin Cancer Res"},{"key":"5227_CR94","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s00432-010-0887-7","volume":"137","author":"C Hontscha","year":"2011","unstructured":"Hontscha C, Borck Y, Zhou H et al (2011) Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC). J Cancer Res Clin Oncol 137:305\u2013310","journal-title":"J Cancer Res Clin Oncol"},{"key":"5227_CR95","doi-asserted-by":"crossref","first-page":"523","DOI":"10.4049\/jimmunol.1301342","volume":"192","author":"A Volonte","year":"2014","unstructured":"Volonte A, Tomaso TD, Spinelli M et al (2014) Cancer-initiating cells from colorectal cancer patients escape from T cell-mediated immunosurveillance in vitro through membrane-bound IL-4. J Immunol 192:523\u2013532","journal-title":"J Immunol"},{"key":"5227_CR96","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/j.1749-6632.2009.04568.x","volume":"1176","author":"T Schatton","year":"2009","unstructured":"Schatton T, Frank MH (2009) Antitumor immunity and cancer stem cells. Ann N Y Acad of Sci 1176:154\u2013169","journal-title":"Ann N Y Acad of Sci"},{"key":"5227_CR97","doi-asserted-by":"crossref","first-page":"84594","DOI":"10.18632\/oncotarget.13141","volume":"7","author":"N Mukherjee","year":"2016","unstructured":"Mukherjee N, Almeida A, Partyka KA et al (2016) Combining a GSI and BCL-2 inhibitor to overcome melanoma's resistance to current treatments. Oncotarget 7:84594\u201384607","journal-title":"Oncotarget"},{"key":"5227_CR98","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1016\/j.febslet.2010.05.061","volume":"584","author":"LW Thomas","year":"2010","unstructured":"Thomas LW, Lam C, Edwards SW (2010) Mcl-1; the molecular regulation of protein function. FEBS Lett 584:2981\u20132989","journal-title":"FEBS Lett"},{"key":"5227_CR99","doi-asserted-by":"crossref","first-page":"46801","DOI":"10.18632\/oncotarget.8695","volume":"8","author":"N Mukherjee","year":"2017","unstructured":"Mukherjee N, Lu Y, Alemeida A et al (2017) Use of a MCL-1 inhibitor alone to de-bulk melanoma and in combination to kill melanoma initiating cells. Oncotarget 8:46801\u201346817","journal-title":"Oncotarget"},{"key":"5227_CR100","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1002\/stem.1160","volume":"30","author":"R Santini","year":"2012","unstructured":"Santini R, Vinci MC, Pandolfi S et al (2012) HEDGEHOG-GLI signaling drives self-renewal and tumorigenicity of human melanoma-initiating cells. Stem Cells 30:1808\u20131818","journal-title":"Stem Cells"},{"key":"5227_CR101","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.1038\/onc.2014.71","volume":"33","author":"R Santini","year":"2014","unstructured":"Santini R, Pietrobono S, Pandolfi S et al (2014) SOX2 regulates self-renewal and tumorigenicity of human melanoma-initiating cells. Oncogene 33:4697\u20134708","journal-title":"Oncogene"},{"key":"5227_CR102","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1007\/s00262-011-1063-x","volume":"60","author":"T Miyabayashi","year":"2011","unstructured":"Miyabayashi T, Kagamu H, Koshio J et al (2011) Vaccination with CD133+ melanoma induces specific Th17 and Th1 cell-mediated antitumor reactivity against parental tumor. Cancer Immunol Immunother 60:1597\u20131608","journal-title":"Cancer Immunol Immunother"},{"key":"5227_CR103","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1007\/s00262-013-1467-x","volume":"62","author":"J Koshio","year":"2013","unstructured":"Koshio J, Kagamu H, Nozaki K et al (2013) DEAD\/H (Asp-Glu-Ala-Asp\/His) box polipeptide 3, X-linked I san immunogenic target of cancer stem cells. Cancer Immunol Immunother 62:1619\u20131628","journal-title":"Cancer Immunol Immunother"},{"key":"5227_CR104","doi-asserted-by":"crossref","first-page":"e111019","DOI":"10.1371\/journal.pone.0111019","volume":"9","author":"K Nozaki","year":"2014","unstructured":"Nozaki K, Kagamu H, Shoji S et al (2014) DDX3X induces primary EGFR-TKI resistance based on intratumor heterogeneity in lung cancer cells harboring EGFR-activating mutations. PloS ONE 9:e111019","journal-title":"PloS ONE"},{"key":"5227_CR105","doi-asserted-by":"crossref","first-page":"755","DOI":"10.7150\/thno.10804","volume":"5","author":"H Shen","year":"2015","unstructured":"Shen H, Shi S, Zhang Z et al (2015) Coating solid lipid nanoparticles with hyaluronic acid enhances antitumor activity against melanoma stem-like cells. Theranostics 5:755\u2013771","journal-title":"Theranostics"},{"key":"5227_CR106","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.canlet.2017.04.028","volume":"400","author":"Y Wang","year":"2017","unstructured":"Wang Y, Liu M, Jin Y et al (2017) In vitro and in vivo anti-uveal melanoma activity of JSL-1, a novel HDAC inhibitor. Cancer Lett 400:47\u201360","journal-title":"Cancer Lett"},{"key":"5227_CR107","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/imm.13016","volume":"156","author":"CG Bazewicz","year":"2019","unstructured":"Bazewicz CG, Dinavahi SS, Schell TD et al (2019) Aldehyde dehydrogenase in regulatory T cell development, immunity and cancer. Immunology 156:47\u201355","journal-title":"Immunology"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-019-05227-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11033-019-05227-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-019-05227-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,13]],"date-time":"2020-12-13T00:13:39Z","timestamp":1607818419000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11033-019-05227-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,14]]},"references-count":107,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["5227"],"URL":"https:\/\/doi.org\/10.1007\/s11033-019-05227-2","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"type":"print","value":"0301-4851"},{"type":"electronic","value":"1573-4978"}],"subject":[],"published":{"date-parts":[[2019,12,14]]},"assertion":[{"value":"9 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declares that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}